MedTrace Logo

Clinical Trial of the Safety and Tolerability of MMH-522 in Healthy Volunteers

NCT07754279 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-08-10

No results posted yet for this study

Summary

Open-label, non-comparative, non-randomized clinical trial of the safety and tolerability of the drug MMH-450 in healthy volunteers consisting of 4 consecutive stages

Conditions

Interventions

DRUG

MMH-522

Per os, without food (at least 30 minutes before or after meals and any liquid). The tablet is kept in the mouth until completely dissolved. Duration of therapy - 7 days

Sponsors & Collaborators

  • Materia Medica Holding

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-12
Primary Completion
2026-04-16
Completion
2026-05-07

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07754279 on ClinicalTrials.gov